Bristol-Myers Squibb Aktie News

Bristol Myers has struggled to generate growth in recent years. Its high debt load has come down but remains a burden for the business.

Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma.

Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Host Hematology-Focused Investor Event.

Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity. BMY's pipeline and recent acquisitions are unlikely to offset revenue declines, with new therapies facing intense competition and limited blockbuster potential. Financial fundamentals are deteriorating, with falling revenue, EBITDA margins, and net income, while hig...

Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for many patients.